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Second mitochondria-derived activator of caspase (Smac) mimetics are considered as promising anticancer
therapeutics that are currently under investigation in early clinical trials. They induce apoptosis by antagonizing inhibitor
of apoptosis proteins, which are frequently overexpressed in cancer. We previously reported that Smac mimetics,
such as BV6, additionally exert non-apoptotic functions in glioblastoma (GBM) cells by stimulating migration and
invasion in a nuclear factor kappa B (NF-κB)-dependent manner. Because NF-κB target genes mediating these effects
are largely unknown, we performed whole-genome expression analyses. Here, we identify chemokine (C-C motif)
ligand 2 (CCL2) as the top-listed NF-κB-regulated gene being upregulated upon BV6 treatment in GBM cells. BV6-
induced upregulation and secretion of CCL2 are required for migration and invasion of GBMcells because knockdown
of CCL2 in GBM cells abolishes these effects. Co-culture experiments of GBM cells with non-malignant astroglial cells
reveal that BV6-stimulated secretion of CCL2 by GBM cells into the supernatant triggers migration of astroglial cells
towardGBMcells becauseCCL2 knockdown inBV6-treatedGBMcells impedesBV6-stimulatedmigration of astroglial
cells. In conclusion, we identify CCL2 as a BV6-inducedNF-κB target gene that triggersmigration and invasion of GBM
cells and exerts paracrine effects on the GBM's microenvironment by stimulating migration of astroglial cells. These
findings provide novel insights into the biological functions of Smac mimetics with important implications for the
development of Smac mimetics as cancer therapeutics.
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Gliomas are the most common primary tumors of the central nervous
system and represent a heterogeneous group of neoplasms, among
which glioblastoma (GBM) is the most malignant and most frequent
tumor entity [1]. Treatment failure of GBM, its poor prognosis, and
its recurrence are largely due to resistance to programmed cell death
[2,3] as well as to its migratory and invasive phenotype [4]. Inhibitor
of apoptosis (IAP) proteins are a family of antiapoptotic proteins that
are frequently overexpressed in cancers including GBM and confer
resistance to cell death by blocking programmed cell death [5].
Furthermore, IAP proteins are involved in the regulation of additional
signal transduction pathways, including the control of cell motility,
migration, invasion, and metastasis [6]. Small-molecule second
mitochondria-derived activator of caspases (Smac)mimetics bind to and
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therapeutic agents [7]. Several studies documented that inhibition of
IAP proteins by Smac mimetics sensitizes GBM cells to temozolomide-
or radiotherapy-induced apoptosis [8–10]. Furthermore, there is
mounting evidence showing that Smac mimetics can also exert
additional functions besides regulating cell death. We previously
reported that the Smac mimetic BV6 promotes migration and invasion
of GBM cells in an nuclear factor kappa B (NF-κB)-dependent manner
[11]. However, the NF-κB target genes that mediate this BV6-
stimulated migration and invasion of GBM cells remain largely
unknown. Therefore, the aim of the present study is to identify key
NF-κB target genes that mediate migration and invasion of GBM cells
upon treatment with Smac mimetics.
Material and Methods
Cell Culture and Chemicals
Human GBM cell lines A172, T98G, and U87MG and human
pediatric astroglial cell lines NHA-E6/E7/hTERT and SVG were
obtained from ATCC (Manassas, VA) and grown in Dulbecco’s
modified Eagle’s medium (Invitrogen, Karlsruhe, Germany)
supplemented with 1% penicillin/streptomycin, 1% sodium
pyruvate (both from Invitrogen), and 10% fetal calf serum
(Invitrogen) at 37°C in a humidified atmosphere with 5% CO2.
NHA-E6/E7/hTERT and SVG cells have previously been
characterized [12,13]. Smac mimetic BV6, which neutralizes
x-linked inhibitor of apoptosis (XIAP), cellular inhibitor of
apoptosis (cIAP)1, and cIAP2 [14], was kindly provided by
Genentech, Inc. (South San Francisco, CA). Human recombinant
chemokine (C-C motif) ligand 2 (hrCCL2 279-MC-010) was
provided from R&D Systems (Minneapolis, MN). All chemicals
were obtained from Sigma (Deisenhofen, Germany) unless
indicated otherwise.
Transduction and siRNA Transfection
Overexpression of the dominant-negative IκBα superrepressor
(IκBα-SR) was performed by retroviral transduction as described
previously [15]. For transient knockdown by siRNA, cells were
reversely transfected with 5 nM (T98G) or 10 nM (U87MG) control
siRNA (SilencerSelect siRNA 4390843, Invitrogen) or targeting
siRNAs (SilencerSelect siRNA 142542 and 44845 for chemokine
(C-C motif) ligand 2 [CCL2], Invitrogen) using Lipofectamine
RNAi Max (Invitrogen) and OptiMEM (Life Technologies,
Darmstadt, Germany).
Quantitative Real-Time polymerase chain reaction (PCR)
Total RNA was extracted using the peqGOLD Total RNA kit
from Peqlab Biotechnologie GmbH (Erlangen, Germany) accord-
ing to the manufacturer’s protocol. Total RNA (300 ng) was used
to synthesize the corresponding cDNA using RevertAid H Minus
First Strand cDNA Synthesis Kit (Thermo Scientific First Strand
cDNA synthesis kit, Germany). To quantify gene expression levels,
SYBR-Green-based quantitative PCR was performed using the
7900HT fast real-time PCR system from Applied Biosystems
(Darmstadt, Germany). Data were normalized to 28S rRNA
expression as reference gene. Primer sequences are listed in
Supplementary Table 1. Melting curves are depicted to verify the
specificity of the amplified products. The relative expression of the
target gene transcript and reference gene transcript was calculated
as ΔΔCt.Gene Expression Profiling
Gene expression profiling was performed as previously described
[16]. Briefly, A172 empty vector (EV) and IκBα-SR cells were treated
for 9 hours with 2 μM BV6 or DMSO as solvent. Total RNA was
extracted using peqGOLD Total RNA kit from Peqlab Biotechno-
logie GmbH (Erlangen, Germany) according to the manufacturer’s
instructions, including DNase digestion. Gene expression profiling
was performed using Illumina Whole-Genome Expression Beadchips
Human HT12v4. For target gene identification, genes were ranked
according to their fold upregulation in vector control cells. Genes that
were similarly regulated in IκBα-SR cells or did not show significant
differences in expression levels in both treated conditions were
removed from the data set (P b 1.25 × 10−6).
Determination of Cell Viability
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay according to the manufacturer’s
instructions (Roche Diagnostics, Mannheim, Germany).
Western Blotting
Western blot analysis was performed as described previously [17] using
the following antibodies: anti-cIAP1 (R&D Systems, Inc., Wiesbaden-
Nordenstadt, Germany), anti-cIAP2 (Epitomics, Burlingam, CA),
anti-XIAP from BD Biosciences, anti–phospho-p65 from Cell Signaling
(Beverly, MA), anti-phospho-IκBα and anti-IκBα (Cell Signaling), anti-
β-actin (Sigma), anti-p65, and anti-p52 from Santa Cruz Biotechnology
(Santa Cruz, CA). Donkey anti-mouse IgG, donkey anti-rabbit IgG, or
donkey anti-goat IgG labeled with IRDye infrared dyes was used for
fluorescence detection at 680 or 800 nm (LI-COR Biotechnology, Bad
Homburg, Germany).
Cytokine Quantification
CCL2 concentrations in glioma cell supernatants were quantified
using CCL2 Flex Sets (BD Biosciences). Samples were analyzed by
fluorescence-activated cell sorting (FACS) and processed with BD
Biosciences FCAP software.
Determination of Migration and Invasion
A total of 0.2 × 105 cells were seeded onto 8-mm Transwell
migration chambers (Corning Inc., Wiesbaden, Germany) and
stimulated by adding 2.5 μM BV6 (GBM and NHA-E6/E7/
hTERT cells) or 1 μM BV6 (SVG cells) to both the lower and the
upper chambers to avoid any gradient effect. Following incubation for
24 hours, cells on the upper part of the membrane were scraped using
a cotton swab. Migrated cells on the membrane were fixed in
paraformaldehyde (4% in cold phosphate-buffered saline [PBS]) and
stained with 4’-6-diamidino-2-phenylindole (Life Technologies,
Carlsbad, CA). Migrated cells were counted on the underside of the
membrane using a fluorescent microscope. The total average number
of migrated/invaded cells in five predefined fields of view per insert
was taken to quantify the total number of migrated cells. CCL2
stimulation experiments were performed by adding increasing concen-
trations of CCL2 (1-10 ng/ml) to the lower chamber of a 24-well plate to
establish a CCL2 gradient for astroglial attraction. For CCL2 stimulation
ofGBMcells, cells were preincubated with 1 ng/ml CCL2 for 10minutes
prior to migration start. Here, CCL2 was added to the upper and lower
chambers of a 24-well plate to avoid any gradient. In vitro invasiveness
of glioma cell lines was examined using 8-mm transwell migration
chambers (Corning Inc., Wiesbaden, Germany) that were coated with
diluted matrigel (1:3 in cold PBS). Glioma cells were seeded at a density
Table 1. Top Five BV6-Induced Genes
Gene Symbol Reference Sequence Fold Increase SD
CCL2 NM_002982.3 8.6 ±0.3
VCAM1 NM_001078.2 5.7 ±0.2
BIRC3 NM_001165.3 4.2 ±0.2
CCL5 NM_002985.2 3.0 ±0.2
IRAK2 NM_001570.3 2.9 ±0.2
A172 cells transfected with EV or IκBα were treated for 9 hours with 2 μM BV6. Gene expression
profiling was performed using Illumina Whole-Genome Expression Beadchips Human HT12v4.
Expression data were ranked according to their fold upregulation comparing EV transfected cells
with and without BV6 treatment. Genes showing upregulation in IκBα-SR transfected cells (with
and without BV6 treatment) served as background expression and were excluded from the analysis
(P b 1.25 × 10−6). Top five BV6-induced genes are shown. Fold increase in mRNA levels is shown
with mean and SD of three independent experiments. VCAM1, vascular cell adhesion molecule;
BIRC3, baculoviral IAP repeat containing 3, also called cIAP2; CCL5, chemokine (C-C motif)
ligand 5; IRAK2, interleukin-1 receptor-associated kinase 2.
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culture plate. After incubation for 24 hours, cells were fixed and stained
using the sameprotocol as described above for the transwellmigration assay.
Co-culture Experiments
T98G or U87MG glioma cells were seeded at 0.2 × 105 cells/ml in
the bottom chamber of transwell inserts, treated with 2.5 μM BV6 to
stimulate CCL2 release, and co-cultured with astroglial SVG and
NHA-E6/E7/hTERT cells (density NHA-E6/E7/hTERT: 0.2 × 105
cells and SVG: 0.6 × 105 cells per insert) for 24 hours. For CCL2
knockdown experiments, T98G or U87MG cells in the bottom
chamber were transiently transfected by siRNA against CCL2 on day
1. On day 2, medium was changed; and on day 3, cells were
pretreated with 2.5 μM BV6 for 4 hours to stimulate CCL2 release.
After 4 hours, medium was changed; GBM cells were washed with
PBS twice; and fresh medium was added. After additional 5 hours
(U87MG) or 11 hours (T98G), co-culture with astroglial cell lines
SVG and NHA-E6/E7/hTERT was started for 24 hours.
Statistical Analysis
Statistical significance was assessed by two-sided Student’s t test
(two-tailed distribution, two samples, unequal variance) using Microsoft
Excel (Microsoft Deutschland GmbH, Unterschleißheim, Germany).
Results
Identification of CCL2 as a Key NF-κB Target Gene that Is
Upregulated and Secreted upon BV6 treatment in GBM Cells
Based on our previous findings showing that the Smac mimetic
BV6 stimulates migration and invasion of GBM cells in an NF-κB-
dependent manner ([11] and Supplementary Figure 1), in the present
study, we aimed to identify key NF-κB target genes mediating these
effects. To address this question, we performed whole-genome
expression profiling in an NF-κB-proficient and -deficient system to
filter for Smac mimetic-induced NF-κB-regulated genes. Interestingly,
we identified CCL2, a member of the CC chemokine family, as the
top-listed NF-κB-regulated gene that is differentially upregulated upon
treatment with BV6 in vector control compared to IκBα-SR-
overexpressing cells (Table 1). Quantitative real-time PCR analysis
confirmed that IκBα-SR overexpression prevented BV6-stimulated
increase in CCL2 mRNA expression (Figure 1A), demonstrating
that BV6 triggers upregulation of CCL2 in an NF-κB-dependent
manner. Additional validation experiments showed that non-toxic
concentrations of BV6 (Supplementary Figure 2A) significantlyincreased CCL2 mRNA levels in two other GBM cell lines
(Figure 1B). Furthermore, we determined whether this upregulation
of CCL2mRNA expression also translates into increased CCL2 protein
expression. Notably, BV6 significantly enhanced the secretion of CCL2
protein into the supernatant of GBM cells (Figure 1C). These
experiments demonstrate that BV6 upregulates CCL2 mRNA levels
and significantly increases CCL2 secretion by GBM cells in an
NF-κB-dependent manner.
BV6-Induced Upregulation of CCL2 Triggers Migration and
Invasion in GBM Cells
As CCL2 has been described to regulate migration and invasion in
several cancer types [18,19], we analyzed whether BV6-induced
upregulation of CCL2 alters migration and invasion of GBM cells. To
genetically block CCL2 signaling, we created CCL2 knockdown cells,
in which CCL2 mRNA expression and protein secretion were
significantly suppressed (Figure 2A and B). Importantly, CCL2
silencing significantly reduced the BV6-stimulated migration and
invasion of GBM cells compared to control siRNA (siCtrl) (Figure 2C
and D). In addition, we used exogenous application of hrCCL2
protein as a positive control to demonstrate that CCL2 stimulates
migration of GBM cells. Addition of hrCCL2 significantly increased
migration of GBM cells in comparison to non-treated cells
(Figure 2E). These results demonstrate that BV6-mediated upregu-
lation of CCL2 contributes to the increased migration and invasion of
GBM cells.
BV6 Causes Depletion of IAP Proteins and NF-κB Activation
in Astroglial Cells
Next, we investigated the effect of BV6 on non-malignant cells of
the tumor microenvironment using the astroglial cell lines SVG and
NHA-E6/E7/hTERT. Concentrations of BV6 up to 1 μM for SVG
cells and 2.5 μM for NHA-E6/E7/hTERT cells had little effect on
cell viability of astroglial cells (Supplementary Figure 2B). As Smac
mimetics stimulate autoubiquitination of IAP proteins followed by
their proteasomal degradation [14,20,21], we examined IAP protein
levels upon BV6 treatment. BV6 treatment caused downregulation of
cIAP1, cIAP2, and XIAP in SVG and NHA-E6/E7/hTERT cells
(Figure 3A). We then examined the effect of BV6 on NF-κB pathway
activity in SVG and NHA-E6/E7/hTERT cells, as BV6-mediated
depletion of IAP proteins has previously been reported to induce
NF-κB activation [14,20,21]. To assess the activity status of the
canonical NF-κB pathway, we analyzed phosphorylation of IκBα and
p65. BV6 stimulated phosphorylation of IκBα and p65 in a
time-dependent manner (Figure 3B). Furthermore, BV6 triggered
processing of p100 to p52, known as a marker for non-canonical
NF-κB activation (Figure 3B). These experiments show that BV6
stimulates depletion of IAP proteins and activates NF-κB signaling in
astroglial cells.
BV6-Stimulated GBM Cells Induce Astroglial Cell Migration
in a Co-culture Model
We then asked whether BV6-stimulated NF-κB activation in
astroglial cells also increases their motility. However, treatment with
BV6 did not result in enhanced migration or invasion of SVG and
NHA-E6/E7/hTERT cells (Figure 3C). Next, we determined
whether BV6 upregulates CCL2 expression in astroglial cells.
Although BV6 treatment increased CCL2 mRNA levels in SVG
and NHA-E6/E7/hTERT cells, it did not enhance CCL2 protein
secretion (Supplementary Figure 3A and B). Subsequently, we set up
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Figure 1. BV6-induced, NF-κB-mediated upregulation and secretion of CCL2 in GBM cells. (A) A172 cells expressing SR or EV were treated
with 2 μMBV6 for 9 hours. mRNA expression of CCL2was analyzed by quantitative reverse transcriptase (qRT)-PCR. Fold increase inmRNA
levels is shown with mean and SEM of three independent experiments performed at least in duplicate. (B) T98G and U87MG cells were
treated for indicated times with 2.5 μM BV6. mRNA expression of CCL2 was analyzed by qRT-PCR. Fold increase in mRNA levels is shown
with mean and SEM of three to six independent experiments performed at least in duplicate. * P b .05, ** P b .01, and *** P b .001. (C) T98G
and U87MG cells were treated with 2.5 μM BV6 (12 hours for T98G; 9 hours for U87MG). CCL2 protein expression in supernatants was
determined by FACS analysis. Mean and SD of three to four independent experiments are shown. * P b .05 and ** P b .01.
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which secrete CCL2 as shown in Figure 1C, trigger migration of
astroglial cells. Here, T98G or U87MG glioma cells were pretreated
for 4 hours with BV6 to stimulate release of CCL2 as shown in
Supplementary Figure 4A. Medium was changed after stimulation,
GBM cells were washed with PBS to remove residual BV6, and
SVG or NHA-E6/E7/hTERT cells were seeded in transwell inserts
and allowed to migrate toward GBM cells in the lower
compartment for 24 hours. Interestingly, this co-culture model
revealed a significant increase in migration of SVG and NHA-E6/
E7/hTERT cells toward BV6-pretreated GBM cells compared to
untreated GBM cells (Figure 3D). Together, these experiments
suggest that CCL2 secreted from BV6-treated GBM cells
stimulates astroglial cell migration toward GBM cells, whereas
direct treatment of astroglial cells with BV6 does not alter the
migratory phenotype of astroglial cells.BV6-Induced Upregulation of CCL2 in GBM Cells Induces
Astroglial Cell Migration
To investigate whether BV6-stimulated upregulation and secretion
of CCL2 in GBM cells are required for migration of astroglial cells
toward GBM cells, we performed co-culture experiments after silencing
of CCL2 in GBM cells by RNA interference. Importantly, knockdown
of CCL2 in T98G and U87MG cells significantly prevented
BV6-induced migration of astroglial cells toward GBM cells
(Figure 4A and B, Supplementary Figure 4B). In addition, we used
increasing concentrations of exogenous hrCCL2 protein as a positive
control to demonstrate that CCL2 increases migration of astroglial cells.
Of note, SVG andNHA-E6/E7/hTERT cells migrated toward a CCL2
gradient in a concentration-dependent manner (Supplementary Figure
4C). Together, these results indicate that BV6-induced upregulation
and secretion of CCL2 in GBM cells affect astroglial cells in a paracrine
manner by increasing their migratory phenotype.
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Figure 2. BV6-induced upregulation of CCL2 triggers migration and invasion in GBM cells. (A) Cells were transiently transfected with
siRNA against CCL2 or siCtrl. CCL2 mRNA expression in GBM cells was analyzed by qRT-PCR. Fold change in mRNA is shown with mean
and SEM of three independent experiments performed at least in duplicate. * P b .05 and *** P b .001. (B) CCL2 protein expression in
supernatants was assessed by FACS analysis. Mean and SD of four independent experiments performed in duplicate are shown. * P b .05
and *** P b .001. (C and D) GBM cells were transiently transfected with siRNA against CCL2 or control siRNA and treated with 2.5 μMBV6
or DMSO for 24 hours. Migration was assessed by transwell migration assay (C); and invasion, by matrigel-precoated Transwell migration
chamber (D). Fold increase in migration or invasion relative to untreated cells transfected with control siRNA with mean and SD of four
independent experiments performed at least in duplicate is shown. * P b .05 and *** P b .001. (E) GBM cells were preincubated for 10
minutes with 1 ng/ml recombinant CCL2 and then CCL2 was added to the upper and lower migration chamber at same concentration.
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We previously reported that small-molecule IAP antagonists, such as
the Smac mimetic BV6, can exert non-apoptotic functions in GBM
cells in a context-dependent manner in addition to promoting celldeath. Namely, BV6 at non-toxic concentrations stimulates migra-
tion and invasion of GBM cells via NF-κB activation [11]. However,
the NF-κB target genes that mediate these BV6-triggered migration
and invasion of GBM cells remained largely elusive. Therefore, the
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upper chamber of the transwell plate were co-cultured with T98G or U87MG cells in the bottom chamber that were transiently transfected
with siRNA against CCL2 or siCtrl and pretreated with 2.5 μM BV6 for 4 hours to stimulate cytokine expression. Migration was assessed
after 24 hours by transwell migration assay. Fold increase in migration relative to untreated cells with mean and SD of three to four
independent experiments performed at least in duplicate is shown. * P b .05, ** P b .01, and *** P b .001. (C) Scheme of BV6-induced
upregulation of CCL2 and its influence on GBM cells and the tumor microenvironment. Smac mimetic BV6 activates NF-κB signaling
pathway in GBM and astroglial cells. BV6-induced NF-κB activation in GBM cells induces CCL2 upregulation and triggers migration and
invasion of GBM cells in an autocrine/paracrine manner. CCL2 secretion of BV6-pretreated GBM cells increases migration of cells of
astroglial cells in a paracrine manner.
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upregulated upon BV6 treatment and required for BV6-stimulated
migration and invasion of GBM cells. Using a genome-wide cDNA
microarray analysis, we identify CCL2 as the top-listed NF-κB-
regulated gene upon BV6 treatment. We report that BV6 upregulates
CCL2 expression in GBM cells and its secretion into the supernatant,
which in turn stimulates migration and invasion of GBM cells in an
autocrine/paracrine manner (Figure 4C). In addition, CCL2 secreted
from BV6-pretreated GBM cells exerts paracrine effects on cells of the
tumor microenvironment and promotes migration of astroglial cells
toward GBM cells (Figure 4C). These conclusions are supported by
several findings. First, CCL2 mRNA levels are upregulated in an
NF-κB-dependent manner upon treatment with BV6 because
inhibition of NF-κB activation by IκBα-SR overexpression prevents
BV6-stimulated increase in CCL2 expression. Second, this upregu-
lation of CCL2 occurs at both mRNA and protein levels; and CCL2
protein is then secreted into the supernatant. Third, CCL2 is
indispensable for BV6-induced migration and invasion, as siRNA-
mediated knockdown of CCL2 significantly rescues BV6-imposedmigration and invasion of GBM cells. In addition, the notion that
CCL2 is a critical mediator of BV6-imposed migration of GBM cells
is emphasized by our data showing that exogenous application of
hrCCL2 similarly promotes GBM cell migration. Fourth, pretreat-
ment of GBM cells with BV6 significantly increases migration of
astroglial cells toward GBM cells in co-culture experiments in a
CCL2-dependent manner because CCL2 silencing in GBM cells
abolishes this effect. Taken together, the novelty of our study
particularly resides in the demonstration that BV6-induced upregu-
lation and secretion of CCL2 by GBM cells promote migration and
invasion of both GBM and astroglial cells via autocrine and paracrine
mechanisms. CCL2 stimulates migration and invasion of GBM cells
via an autocrine/paracrine CCL2 loop. In addition, CCL2 affects the
interaction of GBM cells with their microenvironment by stimulating
astroglial cell migration toward GBM cells in a paracrine manner.
CCL2, also called monocyte chemoattractant protein-1, is a member
of the cytokine/chemokine superfamily [22] and a known NF-κB
target gene [23]. CCL2 has previously been reported to be
upregulated upon treatment with Smac mimetics [11,14], depending
488 Smac Mimetic–Induced Upregulation of CCL2/MCP-1 Lindemann et al. Neoplasia Vol. 17, No. 6, 2015on non-canoncial NF-κB signaling as shown by genetic silencing of
NIK [11]. Although BV6 stimulated a much stronger upregulation of
CCL2 expression in T98G cells than in U87MG cells, the increase in
migration and invasion upon treatment with BV6 was comparable in
both cell lines. As U87MG cells express much lower basal CCL2
levels than T98G cells, one possible explanation is that U87MG cells
are more susceptible to BV6-induced CCL2 upregulation. Our
discovery that CCL2 is a key mediator of BV6-induced migration and
invasion of GBM cells is in line with previous studies underscoring
the importance of CCL2 for the malignant phenotype of cancers
including GBM. For example, increased CCL2 levels were
documented in GBM tissue as compared to adjacent brain tissue
[24,25]. Also, cerebrospinal fluid samples from GBM patients were
described to contain significantly higher levels of CCL2 compared to
patients with no brain tumor [26]. Furthermore, CCL2 has been
shown to function as a chemoattractant for glioma-infiltrating
microglial cells [27]. In addition, antibody-mediated blockade of
CCL2 has been reported to prolong survival in orthotopic glioma
mouse models [28]. The observation that, in a study using one GBM
cell line [29], overexpression of CCL2 was not accompanied by an
increase in invasion suggests that additional factors are involved in the
control of invasion and migration of GBM cells. This notion is
consistent with our findings showing that treatment with BV6 results
in upregulation of other cytokines besides CCL2, including tumor
necrosis factor-α and interleukin-8 [11]. Mechanistically, CCL2-
mediated migration has previously been linked to activation of CC
chemokine receptor type 2, rat sarcoma/rapidly accelerated fibrosarco-
ma 1/mitogen-activated protein kinase/extracellular signal-regulated
kinase and NF-κB pathways, as well as upregulation of matrix
metallopeptidase 9 (MMP-9) in chondrosarcoma cells [19]. MMPs
have been shown to exert an important role in cancer invasion through
enzymatic degradation of the extracellular matrix [30]. MMP-9 may be
involved in BV6-induced invasion of GBM cells, because we previously
demonstrated that MMP-9 is upregulated upon BV6 treatment in GBM
cells [11]. CCL2 has been reported in the past to act both on tumor cells
and, as a chemoattractant, on cells of the tumor microenvironment.
Several tumor types, including myeloma, breast cancer, and prostate
cancer, have been described to express CC chemokine receptor type 2 and
to secrete CCL2, thereby engaging an autocrine/paracrine loop that can
trigger chemotactic migration and invasion of cancer cells [18,19,31,32].
Moreover, it has been reported that CCL2 contributes to the
development of a so-called metastatic niche in the bone marrow
compartment by stimulating the recruitment of monocytes/macrophages
and angiogenesis [33]. Consistently, we show that BV6-induced CCL2
expression and secretion affect not only GBM cells but also cells of the
GBM's microenvironment in a paracrine manner. We demonstrate that
CCL2 secretion into the supernatant of BV6-treated GBM cells alters
communication of GBM cells with non-malignant cells of the central
nervous system by triggering the recruitment of astroglial cells toward
GBM cells. BV6-induced CCL2 secretion is required for the GBM
cell-mediated attraction of astroglial cells because CCL2 knockdown in
GBM cells abolishes BV6-induced secretion of CCL2 by GBM cells and
astroglial cell migration toward GBM cells. By comparison, treatment of
astroglial cells with non-toxic concentrations of BV6 does not increase
their migratory or invasive phenotype, although BV6 depletes IAP
proteins and activatesNF-κB in these cells. This finding is in line with our
observation that BV6 treatment of astroglial cells does not result in
secretion of CCL2 protein, whereas it upregulates CCL2 mRNA levels.
One possible explanation for these findings is that astroglial cells maydifferentially respond to activation by CCL2 compared to GBM cells, for
example, by increased proliferation and upregulation of cellular and
molecular markers of activated astroglial cells [34]. In addition to the
identification of CCL2 as an important mediator of BV6-induced
migration and invasion of GBM cells, our study underscores that Smac
mimetics are involved in the regulation of non-apoptotic pathways
beyond the control of cell death. In this respect, we previously showed
that the Smac mimetic BV6 induces astrocytic differentiation of cancer
stem-like cells by activating NF-κB [35]. Furthermore, we demonstrated
that BV6 stimulates cytokine secretion and monocyte recruitment via
activation of interferon regulatory factor 1 [36]. In addition to CCL2, we
reported that tumor necrosis factor-α autocrine/paracrine signaling
contributes to BV6-induced migration and invasion of GBM cells [11].
Whereas depletion of IAP proteins has been documented by other
investigators to result in increased migration [37,38], consistent with our
findings, IAP proteins have also been described to promote migration
[39–41]. This indicates that IAP proteins play a complex role in the
regulation of cancer cell migration. Smac mimetics are currently under
evaluation in early clinical trials [42]. Therefore, further insights into the
spectrum of their biological functions, including also potentially
undesirable therapeutic effects, have important implications for the
transfer of this approach into clinical application for the treatment of
cancer. By identifying BV6-induced upregulation and secretion of CCL2
as key mediators of migration and invasion of GBM cells and their
interaction with astroglial cells, our study contributes to a better
understanding of Smac mimetic–mediated effects in GBM cells.
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